Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
2.
Leukemia ; 31(11): 2503-2514, 2017 11.
Article in English | MEDLINE | ID: mdl-28232744

ABSTRACT

The initial stages of T-cell differentiation are characterized by a progressive commitment to the T-cell lineage, a process that involves the loss of alternative (myelo-erythroid, NK, B) lineage potentials. Aberrant differentiation during these stages can result in T-cell acute lymphoblastic leukemia (T-ALL). However, the mechanisms regulating the initial stages of human T-cell differentiation are obscure. Through loss of function studies, we showed BCL11B, a transcription factor recurrently mutated T-ALL, is essential for T-lineage commitment, particularly the repression of NK and myeloid potentials, and the induction of T-lineage genes, during the initial stages of human T-cell differentiation. In gain of function studies, BCL11B inhibited growth of and induced a T-lineage transcriptional program in T-ALL cells. We found previously unknown differentiation stage-specific DNA binding of BCL11B at multiple T-lineage genes; target genes showed BCL11B-dependent expression, suggesting a transcriptional activator role for BCL11B at these genes. Transcriptional analyses revealed differences in the regulatory actions of BCL11B between human and murine thymopoiesis. Our studies show BCL11B is a key regulator of the initial stages of human T-cell differentiation and delineate the BCL11B transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL.


Subject(s)
Cell Differentiation/genetics , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Repressor Proteins/genetics , T-Lymphocytes/cytology , Tumor Suppressor Proteins/genetics , Humans
3.
J Nutr Health Aging ; 21(1): 92-104, 2017.
Article in English | MEDLINE | ID: mdl-27999855

ABSTRACT

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The outcomes and impact of synergies are using the Monitoring and Assessment Framework for the EIP on AHA (MAFEIP). Eight proposals for synergies have been approved by the Task Force: Five cross-cutting synergies which can be used for all current and future synergies as they consider overarching domains (appropriate polypharmacy, citizen empowerment, teaching and coaching on AHA, deployment of synergies to EU regions, Responsible Research and Innovation), and three cross-cutting synergies focussing on current Action Group activities (falls, frailty, integrated care and chronic respiratory diseases).


Subject(s)
Aging , Health Behavior , White People , Accidental Falls/prevention & control , Aged , Aged, 80 and over , Chronic Disease , Cooperative Behavior , Europe , Frail Elderly , Humans , Multiple Chronic Conditions , Organizational Innovation , Polypharmacy , Surveys and Questionnaires
4.
Clin Transl Allergy ; 6: 29, 2016.
Article in English | MEDLINE | ID: mdl-27478588

ABSTRACT

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing.

5.
Osteoarthritis Cartilage ; 23(2): 308-18, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25464168

ABSTRACT

OBJECTIVE: Articular cartilage is a highly specialized tissue which forms the surfaces in synovial joints. Full-thickness cartilage defects caused by trauma or microfracture surgery heal via the formation of fibrotic tissue characterized by a high content of collagen I (COL I) and subsequent poor mechanical properties. The goal of this study is to investigate the molecular mechanisms underlying fibrosis after joint injury. DESIGN: Rat knee joint models were used to mimic cartilage defects after acute injury. Immunohistochemistry was performed to detect proteins related to fibrosis. Human fetal chondrocytes and bone marrow stromal cells (BMSCs) were used to study the influence of the lipid lysophosphatidic acid (LPA) on COL I synthesis. Quantitative PCR, ELISA and immunohistochemistry were performed to evaluate the production of COL I. Chemical inhibitors were used to block LPA signaling both in vitro and in vivo. RESULTS: After full-thickness cartilage injury in rat knee joints, stromal cells migrating to the injury expressed high levels of the LPA-producing enzyme autotaxin (ATX); intact articular cartilage in rat and humans expressed negligible levels of ATX despite expressing the LPA receptors LPAR1 and LPAR2. LPA-induced increases in COL I production by chondrocytes and BMSCs were mediated by the MAP kinase and PI3 Kinase signaling pathways. Inhibition of the ATX/LPA axis significantly reduced COL I-enriched fibrocartilage synthesis in full-thickness cartilage defects in rats in favor of the collagen II-enriched normal state. CONCLUSION: Taken together, these results identify an attractive target for intervention in reducing the progression of post-traumatic fibrosis and osteoarthritis.


Subject(s)
Cartilage, Articular/injuries , Cartilage, Articular/pathology , Collagen Type I/biosynthesis , Lysophospholipids/physiology , Stifle/injuries , Animals , Fibrosis/etiology , Humans , Male , Rats , Rats, Sprague-Dawley
6.
Gene Ther ; 16(8): 998-1008, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19440227

ABSTRACT

An important goal of gene therapy is to be able to deliver genes, so that they express in a pattern that recapitulates the expression of an endogenous cellular gene. Although tissue-specific promoters confer selectivity, in a vector-based system, their activity may be too weak to mediate detectable levels in gene-expression studies. We have used a two-step transcriptional amplification system to amplify gene expression from lentiviral vectors using the human insulin promoter. In this system, the human insulin promoter drives expression of a potent synthetic transcription activator (the yeast GAL4 DNA-binding domain fused to the activation domain of the Herpes simplex virus-1 VP16 activator), which in turn activates a GAL4-responsive promoter, driving the enhanced green fluorescent protein reporter gene. Vectors carrying the human insulin promoter did not express in non-beta-cell lines, but expressed in murine insulinoma cell lines, indicating that the human insulin promoter was capable of conferring cell specificity of expression. The insulin-amplifiable vector was able to amplify gene expression five to nine times over a standard insulin-promoter vector. In primary human islets, gene expression from the insulin-promoted vectors was coincident with insulin staining. These vectors will be useful in gene-expression studies that require a detectable signal and tissue specificity.


Subject(s)
Gene Transfer Techniques , Genetic Vectors , Insulin-Secreting Cells/metabolism , Insulin/genetics , Lentivirus/genetics , Transcriptional Activation/genetics , Animals , Cell Line , Gene Expression , Green Fluorescent Proteins/genetics , Humans , Islets of Langerhans/metabolism , Mice , Organ Specificity , Phosphoglycerate Kinase/genetics , Promoter Regions, Genetic
7.
J Chem Phys ; 130(10): 107101; discussion 107102, 2009 Mar 14.
Article in English | MEDLINE | ID: mdl-19292558

ABSTRACT

The incongruous "unexpected inapplicability of the Crook's fluctuation theorem" is due to an inexplicable, inappropriate use of inconsistent expressions. The girding is secure.

8.
Proc Natl Acad Sci U S A ; 101(42): 15038-41, 2004 Oct 19.
Article in English | MEDLINE | ID: mdl-15469914

ABSTRACT

Most natural processes occur far from equilibrium and cannot be treated within the framework of classical thermodynamics. In 1998, Oono and Paniconi [Oono, Y. & Paniconi, M. (1998) Prog. Theor. Phys. Suppl. 130, 29-44] proposed a general phenomenological framework, steady-state thermodynamics, encompassing nonequilibrium steady states and transitions between such states. In 2001, Hatano and Sasa [Hatano, T. & Sasa, S. (2001) Phys. Rev. Lett. 86, 3463-3466] derived a testable prediction of this theory. Specifically, they were able to show that the exponential average of Y, a quantity similar to a dissipated work, should be equal to zero for arbitrary transitions between nonequilibrium steady states, -ln = 0. We have tested this strong prediction by measuring the dissipation and fluctuations of microspheres optically driven through water. We have found that -ln approximately 0 for three different nonequilibrium systems, supporting Hatano and Sasa's proposed extension of thermodynamics to arbitrary steady states and irreversible transitions.


Subject(s)
Thermodynamics , Models, Theoretical
9.
Leukemia ; 16(3): 352-61, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11896538

ABSTRACT

The immortalized murine stromal cell line AFT024 has been reported to maintain human hematopoietic progenitors in an undifferentiated state in vitro. In the current studies the beige/nude/xid (bnx) mouse in vivo xenograft model was used to examine the engraftment and multilineage generative potential of human hematopoietic progenitors after 2-3 weeks growth on AFT024 stroma, in comparison to primary stromal monolayers derived from post-natal human bone marrow. Eight to 12 months after transplantation of human CD34+CD38- cells from umbilical cord blood, cultured on AFT024 vs human stroma for 2-3 weeks, the murine bone marrow was harvested and analyzed for the presence of human myeloid and lymphoid cells. The mean percent engraftment of total human hematopoietic cells in the murine marrow was significantly higher after co-cultivation on AFT024 than on human stroma. Human myeloid and lymphoid lineage cells were detected in all mice. However, engraftment of myeloid lineage cells (CD33+), B lymphoid (CD19+), and T lymphoid cells (CD4+and CD8+) were significantly higher after co-cultivation of the human cells on AFT024 than on human stroma, prior to transplantation. Interestingly, the length of time in culture did not significantly affect the engraftment of the myeloid and T lymphoid lineage progenitors, but the percentage of B lymphoid lineage engraftment decreased significantly between 2 and 3 weeks of co-cultivation on both types of stroma. Cells with a primitive phenotype (CD45+/CD34-/CD38- and CD45+/CD34-/lin-) and cells with the capacity to generate secondary human CFU after recovery from the bnx bone marrow were maintained at significantly higher levels during culture on AFT024 stroma than on human stroma. The current studies demonstrate that the AFT024 murine stromal cell line supports the ex vivo survival and maintenance of human hematopoietic progenitors that are capable of long-term multilineage reconstitution for 2-3 weeks ex vivo, to levels superior to those that can be obtained using human stromal cells.


Subject(s)
Bone Marrow Transplantation/immunology , Hematopoiesis/immunology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/immunology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Animals , Antigens, CD/blood , Antigens, Differentiation , B-Lymphocytes/immunology , Bone Marrow/immunology , Bone Marrow Cells , Cells, Cultured , Fetal Blood/cytology , Graft Survival , Humans , Immunophenotyping , Membrane Glycoproteins , Mice , Mice, SCID , NAD+ Nucleosidase , Stromal Cells/immunology , T-Lymphocytes/immunology , Transplantation, Heterologous
10.
J Immunol ; 167(4): 1867-70, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11489963

ABSTRACT

Murine studies implicate Ikaros proteins as regulators of hemopoiesis, particularly in the lymphoid lineages. High homology between murine and human Ikaros suggests that Ikaros expression in the two might be similar. However, initial human studies that focused on leukemia detected novel Ikaros transcripts in patient samples. Thus, novel Ikaros splice forms and DNA nonbinding isoforms were linked with malignancy. We undertook an extensive analysis of normal human Ikaros expression to determine whether novel mRNAs are expressed as proteins and the extent to which these splice variants are unique to leukemia. Here we show that both mRNA and protein for DNA nonbinding Ikaros isoforms and splice variants previously linked to leukemia are expressed in normal human cells. However, our studies identify a new Ikaros isoform not previously described in mouse or human. This isoform is the predominant Ikaros protein in normal human cells, but not in leukemia cell lines.


Subject(s)
Hematopoietic Stem Cells/metabolism , Transcription Factors/biosynthesis , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Cells, Cultured , DNA-Binding Proteins/genetics , Fetal Blood/cytology , Fetal Blood/immunology , Fetal Blood/metabolism , Hematopoietic Stem Cells/immunology , Humans , Ikaros Transcription Factor , Jurkat Cells , Leukemia/immunology , Leukemia/metabolism , Mutagenesis, Insertional/immunology , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Protein Isoforms/metabolism , Sequence Deletion/immunology , Transcription Factors/genetics , Transcription Factors/metabolism , Transcription, Genetic/immunology , Tumor Cells, Cultured
11.
Phys Rev E Stat Nonlin Soft Matter Phys ; 64(2 Pt 2): 026109, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11497653

ABSTRACT

The transition path sampling methodology is adapted to the efficient sampling of large fluctuations in nonequilibrium systems evolving according to Langevin's equations of motion. This technique is used to simulate the behavior of the bistable Maier-Stein system at noise intensities much lower than those previously possible.

12.
Blood ; 97(12): 3683-90, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11389003

ABSTRACT

The earliest stages of lymphoid commitment from human pluripotent hematopoietic stem cells have not been defined. A clonogenic subpopulation of CD34(+)CD38(-) cord blood cells were identified that expressed high levels of the CD7 antigen and possessed only lymphoid potential. CD34(+)CD38(-)CD7(+) (CD7(+)) cells uniformly coexpressed CD45RA and HLA-DR; c-kit and Thy-1 expression was absent to low. Clonal analysis demonstrated that single CD7(+) cells could generate B cells, natural killer cells, and dendritic cells but were devoid of myeloid or erythroid potential. In contrast, control CD34(+)CD38(-)CD7(-) (CD7(-)) cells generated both lymphoid and myelo-erythroid cells. The lymphoid potential (generation of lymphoid progeny in bulk and single cell cultures) of CD7(+) cells was equivalent to that of the pluripotent CD7(-) cells. RNA expression studies showed that CD7(+) cells expressed PU.1 and GATA-3, but did not express Pax-5, terminal deoxynucleotide transferase, or CD3epsilon. In contrast to the previously described murine common lymphoid progenitor, the alpha chain of the receptor for interleukin-7 was not detected by fluorescence-activated cell sorting analysis or RNA polymerase chain reaction in CD7(+) cells. These studies identify a clonogenic lymphoid progenitor with both B-cell and natural killer cell lineage potential with a molecular profile that suggests a developmental stage more primitive than previously identified lymphoid progenitors. The CD7(+) phenotype distinguishes primitive human lymphoid progenitors from pluripotent stem cells, thus allowing the study of regulation of early human lymphopoiesis and providing an alternative to pluripotent stem cells for genetic manipulation and transplantation. (Blood. 2001;97:3683-3690)


Subject(s)
Antigens, CD , Cell Lineage , Fetal Blood/cytology , Hematopoietic Stem Cells/cytology , Lymphocyte Subsets/immunology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Antigens, CD34/blood , Antigens, CD7/blood , Antigens, Differentiation/blood , B-Lymphocytes/cytology , Cell Differentiation , Clone Cells/cytology , Clone Cells/immunology , Dendritic Cells/cytology , Fetal Blood/immunology , Hematopoiesis , Hematopoietic Stem Cells/immunology , Humans , Immunophenotyping , Killer Cells, Natural/cytology , Lymphocytes/cytology , Membrane Glycoproteins , NAD+ Nucleosidase/blood , RNA, Messenger/analysis
13.
Blood ; 97(12): 3925-30, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11389036

ABSTRACT

Successful autologous hematopoietic stem cell (HSC) transplantation in childhood acute lymphoblastic leukemia (ALL) requires the ability to either selectively kill the leukemia cells or separate normal from leukemic HSC. Based on previous studies showing that more than 95% of childhood B-lineage ALL express CD38, this study evaluated whether normal CD34(+)CD38(-) progenitors from children with B-lineage ALL could be isolated by flow cytometry. CD34(+) cells from bone marrow samples from 10 children with B-lineage ALL were isolated at day 28 of treatment, when clinical remission had been attained. The CD34(+) progenitor cells were flow cytometrically sorted into CD34(+)CD38(+) and CD34(+)CD38(-) populations. The absolute numbers of CD34(+)CD38(-) cells that could be isolated ranged from 401 to 6245. The cells were then analyzed for the presence of clonotypic rearrangements of the T-cell receptor (TCR) Vdelta2-Ddelta3 locus. Only patients whose diagnostic marrow had an informative TCR Vdelta2-Ddelta3 rearrangement were included in this study. Detection thresholds were typically 10(-4) to 10(-5) leukemic cells in normal marrow. In 6 of 10 samples analyzed, the sorted CD34(+)CD38(-) cells had no detectable Vdelta2-Ddelta3 rearrangements. In 4 cases, the clonotypic leukemic Vdelta2-Ddelta3 rearrangement was detected in the CD34(+)CD38(-) population, indicating that the putative normal HSC population also contained leukemic cells. The data indicate that although most childhood ALL cells express CD34 and CD38, leukemic cells are also frequently present in the CD34(+)CD38(-) population. Therefore, strategies to isolate and transplant normal HSC from children with ALL will require a more stringent definition of the normal HSC than the CD34(+)CD38(-) phenotype. (Blood. 2001;97:3925-3930)


Subject(s)
Antigens, CD34/analysis , Antigens, CD , Antigens, Differentiation/analysis , Bone Marrow Purging/standards , Hematopoietic Stem Cells , NAD+ Nucleosidase/analysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , B-Lymphocytes/pathology , Blotting, Southern , Bone Marrow/pathology , Child , Clone Cells , DNA, Neoplasm/analysis , Flow Cytometry , Gene Rearrangement , Genes, T-Cell Receptor delta , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Membrane Glycoproteins , Polymerase Chain Reaction , Remission Induction
15.
Curr Allergy Asthma Rep ; 1(5): 416-20, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11892067

ABSTRACT

Hematopoietic stem cell transplantation (HSCT) has been the definitive therapy for severe combined immune deficiency (SCID) since the first successful transplant for SCID in 1968. Improvements in the use of HSCT to treat patients with SCID are continuing. For example, during the last 5 years, the first successful in-utero HSCT, and the first success with gene therapy have occurred in patients with SCID. Debate still continues about the role of pretransplantation therapy for SCID patients, and the biology of post-HSCT immune reconstitution is under investigation.


Subject(s)
Hematopoietic Stem Cell Transplantation , Severe Combined Immunodeficiency/therapy , Genetic Therapy , Humans , Severe Combined Immunodeficiency/immunology , Severe Combined Immunodeficiency/surgery
16.
J Immunol ; 165(5): 2382-9, 2000 Sep 01.
Article in English | MEDLINE | ID: mdl-10946261

ABSTRACT

The effect of IL-3 on the B lymphoid potential of human hemopoietic stem cells is controversial. Murine studies suggest that B cell differentiation from uncommitted progenitors is completely prevented after short-term exposure to IL-3. We studied B lymphopoiesis after IL-3 stimulation of uncommitted human CD34+CD38- cells, using the stromal cell line S17 to assay the B lymphoid potential of stimulated cells. In contrast to the murine studies, production of CD19+ B cells from human CD34+CD38- cells was significantly increased by a 3-day exposure to IL-3 (p < 0.001). IL-3, however, did not increase B lymphopoiesis from more mature progenitors (CD34+CD38+ cells) or from committed CD34-CD19+ B cells. B cell production was increased whether CD34+CD38- cells were stimulated with IL-3 during cocultivation on S17 stroma, on fibronectin, or in suspension. IL-3Ralpha expression was studied in CD34+ populations by RT-PCR and FACS. High IL-3Ralpha protein expression was largely restricted to myeloid progenitors. CD34+CD38- cells had low to undetectable levels of IL-3Ralpha by FACS. IL-3-responsive B lymphopoiesis was specifically found in CD34+ cells with low or undetectable IL-3Ralpha protein expression. IL-3 acted directly on progenitor cells; single cell analysis showed that short-term exposure of CD34+CD38- cells to IL-3 increased the subsequent cloning efficiency of B lymphoid and B lymphomyeloid progenitors. We conclude that short-term exposure to IL-3 significantly increases human B cell production by inducing proliferation and/or maintaining the survival of primitive human progenitors with B lymphoid potential.


Subject(s)
Antigens, CD34/biosynthesis , Antigens, CD , Antigens, Differentiation/biosynthesis , B-Lymphocyte Subsets/cytology , B-Lymphocyte Subsets/immunology , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Interleukin-3/physiology , NAD+ Nucleosidase/biosynthesis , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Adjuvants, Immunologic/physiology , Antigens, CD19/biosynthesis , B-Lymphocyte Subsets/metabolism , Cell Culture Techniques , Cell Differentiation/immunology , Cells, Cultured , Child , Child, Preschool , Drug Combinations , Hematopoietic Stem Cells/metabolism , Humans , Interleukin-7/physiology , Ligands , Membrane Glycoproteins , Membrane Proteins/physiology , Stromal Cells/immunology , Time Factors
17.
Mol Ther ; 2(1): 71-80, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10899830

ABSTRACT

Lentiviral vectors have been proposed as a more efficient alternative to Moloney murine leukemia virus-based retroviral vectors for transduction of human hematopoietic progenitors and stem cells. These studies were designed to evaluate the conditions that influence transduction frequency of CD34(+) progenitors, with the goal of optimizing efficiency of stable gene transfer with lentiviral vectors. CD34(+) human cord blood cells and 293 cells were transduced with a human immunodeficiency virus (HIV)-1 derived lentiviral vector pseudotyped with vesicular stomatitis virus glycoprotein and carrying an internal human cytomegalovirus promoter driving enhanced green fluorescent protein (eGFP) expression. Using fluorescence-activated cell sorting analysis of eGFP, we observed pseudotransduction beginning at the time of vector addition and lasting up to 24 h in CD34(+) cells and up to 72 h in 293 cells. Integrase-defective lentiviral vector caused transient eGFP expression for up to 10 days in CD34(+) cells and for up to 14 days in 293 cells. Protamine sulfate conferred no increase in transduction efficiency of CD34(+) cells on fibronectin-coated plates. Transduction frequency was related directly to vector concentration and not to multiplicity of infection across the ranges tested. First- and second-generation lentiviral vectors transduced CD34(+) cells equally, demonstrating a lack of dependence on HIV-1 accessory proteins. These findings will be useful for the optimal utilization of this new class of vectors for transduction of human hematopoietic stem cells.


Subject(s)
Antigens, CD34/genetics , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Lentivirus/genetics , Membrane Glycoproteins , Transduction, Genetic , Cell Line , Cell Separation , Cytomegalovirus/genetics , Fetal Blood/cytology , Fibronectins/metabolism , Flow Cytometry , Gene Transfer Techniques , Green Fluorescent Proteins , HIV-1/genetics , Heparin Antagonists/pharmacology , Humans , Luminescent Proteins/metabolism , Plasmids/metabolism , Promoter Regions, Genetic , Protamines/pharmacology , Time Factors , Transfection , Viral Envelope Proteins/genetics
18.
Arch Immunol Ther Exp (Warsz) ; 48(2): 111-8, 2000.
Article in English | MEDLINE | ID: mdl-10807052

ABSTRACT

Severe combined immunodeficiency (SCID) is fatal in early childhood if unrecognized and if not treated. The aim was to determine the efficacy of T cell depleted bone marrow transplantation (TCD BMT) in the treatment of children with SCID. Eleven children diagnosed with SCID received histocompatible related donor bone marrow transplantation--HRD BMT (group I). Thirty seven children diagnosed with SCID who did not have histocompatible donors were treated with TCD haploidentical parental bone marrow transplantation (BMT) (group II). TCD was performed by in vitro soybean lectin agglutination followed by E-rosette depletion. Patients were longitudinally assessed for the presence and function of T and B lymphocytes. In group I all children survived. The mean age of children in this group at the time of HRD BMT was 15.4 months. All surviving patients normalized their specific T cell function. Two out of 11 require treatment with intravenous immunoglobulin i.v. Ig. In group II 17 out of 37 (46%) children survived. At the time of TCD BMT the mean age of survivors was 7.5 months, vs. 11.4 months in patients who died. Death was caused most commonly by opportunistic infections, Epstein-Barr virus induced lymphoproliferative disease (EBV-LPD), and graft versus host disease (GvHD). Seventeen out of 17 surviving patients recovered normal numbers of CD3+ cells and antigen specific T cell function. Five out of 17 never recovered their B cell function and require i.v. Ig injections. Early diagnosis, prevention or treatment of opportunistic infections, and enhancement of immune recovery will be necessary to improve survival in patients with SCID treated with TCD BMT.


Subject(s)
Bone Marrow Transplantation , Severe Combined Immunodeficiency/therapy , Adolescent , Bone Marrow Transplantation/immunology , Child , Child, Preschool , Female , Graft Survival , Haplotypes , Histocompatibility , Humans , Living Donors , Lymphocyte Depletion/methods , Male , Nuclear Family , Parents , Severe Combined Immunodeficiency/immunology , T-Lymphocytes/immunology , Transplantation, Homologous
19.
Annu Rev Med ; 51: 33-47, 2000.
Article in English | MEDLINE | ID: mdl-10774451

ABSTRACT

The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (d) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.


Subject(s)
Adenosine Deaminase/deficiency , Genetic Therapy , Animals , Bone Marrow Transplantation , Cyclin-Dependent Kinases/antagonists & inhibitors , Fetal Blood , Fibronectins , Hematopoietic Stem Cell Transplantation , Humans , Immune System Diseases/therapy , Lentivirus , Mice , T-Lymphocytes/transplantation
20.
Blood ; 94(11): 3872-82, 1999 Dec 01.
Article in English | MEDLINE | ID: mdl-10572103

ABSTRACT

Wiskott-Aldrich syndrome (WAS) is an X-linked recessive disorder characterized by thrombocytopenia, eczema, and a progressive deterioration of immune function. WAS is caused by mutations in an intracellular protein, WASP, that is involved in signal transduction and regulation of actin cytoskeleton rearrangement. Because immune dysfunction in WAS may be due to an accelerated destruction of lymphocytes, we examined the susceptibility to apoptosis of resting primary lymphocytes isolated from WAS patients in the absence of exogenous apoptogenic stimulation. We found that unstimulated WAS lymphocytes underwent spontaneous apoptosis at a greater frequency than unstimulated normal lymphocytes. Coincident with increased apoptotic susceptibility, WAS lymphocytes had markedly attenuated Bcl-2 expression, whereas Bax expression did not differ. A negative correlation between the frequency of spontaneous apoptosis and the level of Bcl-2 expression was demonstrated. These data indicate that accelerated lymphocyte destruction by spontaneous induction of apoptosis may be one pathogenic mechanism by which the progressive immunodeficiency in WAS patients develops.


Subject(s)
Apoptosis , Lymphocytes/pathology , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Wiskott-Aldrich Syndrome/pathology , Adolescent , Cell Death , Child, Preschool , Humans , Infant , Lymphocytes/metabolism , Male , Wiskott-Aldrich Syndrome/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...